Company: OPGN
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001829126-25-009312
Chunk: 1

Company: OPGEN INC
Filing Date: 2025-11-19
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
 31, 2024

    2

    2

    Common stock, $0.01 par value; 100,000,000 shares authorized; 10,071,286 and 10,070,779 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively

    100,713

    100,708

    Additional paid-in capital

    301,064,643

    300,780,440

    Accumulated deficit

    (291,007,393
    )

    (293,500,522
    )
  
    Total stockholders’ equity

    10,157,965

    7,380,628

    Total liabilities and stockholders’ equity
     
    $
    12,639,255

    $
    9,862,698

See accompanying notes to unaudited condensed consolidated financial statements.

1

OpGen, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(unaudited)

    Three Months Ended September 30,

    Nine Months Ended September 30,

    2025

    2024

    2025

    2024

    Revenue

    Product sales
     
    $
    -

    $
    -

    $
    -

    $
    169,373

    Laboratory services

    -

    -

    -

    26,776

    Listing sponsorship services

    -

    -

    4,000,000

    -

    Total revenue

    -

    -

    4,000,000

    196,149

    Operating expenses

    Cost of products sold

    -

    -

    -

    31,636

    Cost of services

    -

    -

    -

    1,575

    Research and development, net

    -

    488

    -

    49,308

    General and administrative

    701,915 

    768,551

    1,810,097

    4,021,321

    Sales and marketing

    270 

    14,846

    12,159

    168,819

    Total operating expenses

    702,185

    783,885

    1,822,256

    4,272,659

    Operating (loss) income

    (702